245 related articles for article (PubMed ID: 33596073)
1. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
[TBL] [Abstract][Full Text] [Related]
3. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity.
Pillow TH; Adhikari P; Blake RA; Chen J; Del Rosario G; Deshmukh G; Figueroa I; Gascoigne KE; Kamath AV; Kaufman S; Kleinheinz T; Kozak KR; Latifi B; Leipold DD; Sing Li C; Li R; Mulvihill MM; O'Donohue A; Rowntree RK; Sadowsky JD; Wai J; Wang X; Wu C; Xu Z; Yao H; Yu SF; Zhang D; Zang R; Zhang H; Zhou H; Zhu X; Dragovich PS
ChemMedChem; 2020 Jan; 15(1):17-25. PubMed ID: 31674143
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
5. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
[TBL] [Abstract][Full Text] [Related]
6. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).
Dragovich PS; Adhikari P; Blake RA; Blaquiere N; Chen J; Cheng YX; den Besten W; Han J; Hartman SJ; He J; He M; Rei Ingalla E; Kamath AV; Kleinheinz T; Lai T; Leipold DD; Li CS; Liu Q; Lu J; Lu Y; Meng F; Meng L; Ng C; Peng K; Lewis Phillips G; Pillow TH; Rowntree RK; Sadowsky JD; Sampath D; Staben L; Staben ST; Wai J; Wan K; Wang X; Wei B; Wertz IE; Xin J; Xu K; Yao H; Zang R; Zhang D; Zhou H; Zhao Y
Bioorg Med Chem Lett; 2020 Feb; 30(4):126907. PubMed ID: 31902710
[TBL] [Abstract][Full Text] [Related]
8. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
He S; Gao F; Ma J; Ma H; Dong G; Sheng C
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
[TBL] [Abstract][Full Text] [Related]
10. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
12. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
Zengerle M; Chan KH; Ciulli A
ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of PROTAC cooperative recognition for selective protein degradation.
Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
[TBL] [Abstract][Full Text] [Related]
14. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
15. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
16. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
17. Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC).
Li Z; Ma S; Yang X; Zhang L; Liang D; Dong G; Du L; Lv Z; Li M
Eur J Med Chem; 2021 Oct; 222():113608. PubMed ID: 34119833
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
[TBL] [Abstract][Full Text] [Related]
19. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
20. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]